Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
SOUTH SAN FRANCISCO, Calif., April 08, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 15th Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
